AVANOS MEDICAL INC (AVNS) Fundamental Analysis & Valuation
NYSE:AVNS • US05350V1061
Current stock price
13.6 USD
-0.25 (-1.81%)
Last:
This AVNS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. AVNS Profitability Analysis
1.1 Basic Checks
- In the past year AVNS was profitable.
- AVNS had a positive operating cash flow in the past year.
- In multiple years AVNS reported negative net income over the last 5 years.
- Each year in the past 5 years AVNS had a positive operating cash flow.
1.2 Ratios
- AVNS has a Return On Assets of -6.79%. This is in the better half of the industry: AVNS outperforms 67.20% of its industry peers.
- AVNS has a Return On Equity of -9.37%. This is in the better half of the industry: AVNS outperforms 68.78% of its industry peers.
- The Return On Invested Capital of AVNS (1.47%) is better than 68.25% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for AVNS is significantly below the industry average of 9.31%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.79% | ||
| ROE | -9.37% | ||
| ROIC | 1.47% |
ROA(3y)-14.8%
ROA(5y)-8.25%
ROE(3y)-20.56%
ROE(5y)-11.47%
ROIC(3y)1.82%
ROIC(5y)2.02%
1.3 Margins
- With a decent Operating Margin value of 2.41%, AVNS is doing good in the industry, outperforming 68.25% of the companies in the same industry.
- AVNS's Operating Margin has declined in the last couple of years.
- AVNS has a Gross Margin (50.47%) which is comparable to the rest of the industry.
- AVNS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.41% | ||
| PM (TTM) | N/A | ||
| GM | 50.47% |
OM growth 3Y-36.17%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-0.68%
2. AVNS Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so AVNS is destroying value.
- The number of shares outstanding for AVNS has been increased compared to 1 year ago.
- Compared to 5 years ago, AVNS has less shares outstanding
- AVNS has a better debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 1.21, we must say that AVNS is in the distress zone and has some risk of bankruptcy.
- AVNS has a Altman-Z score (1.21) which is comparable to the rest of the industry.
- The Debt to FCF ratio of AVNS is 2.33, which is a good value as it means it would take AVNS, 2.33 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of AVNS (2.33) is better than 85.71% of its industry peers.
- A Debt/Equity ratio of 0.12 indicates that AVNS is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.12, AVNS is in the better half of the industry, outperforming 64.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 2.33 | ||
| Altman-Z | 1.21 |
ROIC/WACC0.14
WACC10.39%
2.3 Liquidity
- A Current Ratio of 2.15 indicates that AVNS has no problem at all paying its short term obligations.
- AVNS's Current ratio of 2.15 is in line compared to the rest of the industry. AVNS outperforms 41.80% of its industry peers.
- AVNS has a Quick Ratio of 1.26. This is a normal value and indicates that AVNS is financially healthy and should not expect problems in meeting its short term obligations.
- AVNS has a worse Quick ratio (1.26) than 66.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.15 | ||
| Quick Ratio | 1.26 |
3. AVNS Growth Analysis
3.1 Past
- AVNS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.40%.
- AVNS shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.80% yearly.
- Looking at the last year, AVNS shows a small growth in Revenue. The Revenue has grown by 1.95% in the last year.
- AVNS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.38% yearly.
EPS 1Y (TTM)-25.4%
EPS 3Y-17.1%
EPS 5Y3.8%
EPS Q2Q%-30.95%
Revenue 1Y (TTM)1.95%
Revenue growth 3Y-5.08%
Revenue growth 5Y-0.38%
Sales Q2Q%0.72%
3.2 Future
- The Earnings Per Share is expected to grow by 16.51% on average over the next years. This is quite good.
- The Revenue is expected to grow by 3.19% on average over the next years.
EPS Next Y8.62%
EPS Next 2Y16.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.16%
Revenue Next 2Y3.19%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. AVNS Valuation Analysis
4.1 Price/Earnings Ratio
- AVNS is valuated correctly with a Price/Earnings ratio of 14.47.
- Compared to the rest of the industry, the Price/Earnings ratio of AVNS indicates a rather cheap valuation: AVNS is cheaper than 87.83% of the companies listed in the same industry.
- When comparing the Price/Earnings ratio of AVNS to the average of the S&P500 Index (25.23), we can say AVNS is valued slightly cheaper.
- A Price/Forward Earnings ratio of 13.32 indicates a correct valuation of AVNS.
- AVNS's Price/Forward Earnings ratio is rather cheap when compared to the industry. AVNS is cheaper than 89.42% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of AVNS to the average of the S&P500 Index (22.51), we can say AVNS is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.47 | ||
| Fwd PE | 13.32 |
4.2 Price Multiples
- AVNS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AVNS is cheaper than 87.30% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, AVNS is valued cheaply inside the industry as 95.24% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.68 | ||
| EV/EBITDA | 11.74 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- A more expensive valuation may be justified as AVNS's earnings are expected to grow with 16.51% in the coming years.
PEG (NY)1.68
PEG (5Y)3.81
EPS Next 2Y16.51%
EPS Next 3YN/A
5. AVNS Dividend Analysis
5.1 Amount
- AVNS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
AVNS Fundamentals: All Metrics, Ratios and Statistics
NYSE:AVNS (3/27/2026, 10:32:07 AM)
13.6
-0.25 (-1.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-24 2026-02-24/bmo
Earnings (Next)05-04 2026-05-04
Inst Owners97.21%
Inst Owner Change27.64%
Ins Owners2.94%
Ins Owner Change6.58%
Market Cap632.54M
Revenue(TTM)701.20M
Net Income(TTM)-72.90M
Analysts43.33
Price TargetN/A
Short Float %5.84%
Short Ratio4.24
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.19%
Min EPS beat(2)14.64%
Max EPS beat(2)79.74%
EPS beat(4)4
Avg EPS beat(4)36.78%
Min EPS beat(4)11.11%
Max EPS beat(4)79.74%
EPS beat(8)5
Avg EPS beat(8)16.95%
EPS beat(12)7
Avg EPS beat(12)15.54%
EPS beat(16)10
Avg EPS beat(16)13.47%
Revenue beat(2)2
Avg Revenue beat(2)3.74%
Min Revenue beat(2)1.52%
Max Revenue beat(2)5.97%
Revenue beat(4)4
Avg Revenue beat(4)3.17%
Min Revenue beat(4)1.52%
Max Revenue beat(4)5.97%
Revenue beat(8)4
Avg Revenue beat(8)0.74%
Revenue beat(12)4
Avg Revenue beat(12)-0.83%
Revenue beat(16)4
Avg Revenue beat(16)-4.39%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-39.13%
EPS NQ rev (3m)-39.13%
EPS NY rev (1m)5.37%
EPS NY rev (3m)5.37%
Revenue NQ rev (1m)0.29%
Revenue NQ rev (3m)0.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.47 | ||
| Fwd PE | 13.32 | ||
| P/S | 0.9 | ||
| P/FCF | 14.68 | ||
| P/OCF | 8.47 | ||
| P/B | 0.81 | ||
| P/tB | 2.38 | ||
| EV/EBITDA | 11.74 |
EPS(TTM)0.94
EY6.91%
EPS(NY)1.02
Fwd EY7.51%
FCF(TTM)0.93
FCFY6.81%
OCF(TTM)1.61
OCFY11.81%
SpS15.08
BVpS16.73
TBVpS5.71
PEG (NY)1.68
PEG (5Y)3.81
Graham Number18.81
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.79% | ||
| ROE | -9.37% | ||
| ROCE | 1.86% | ||
| ROIC | 1.47% | ||
| ROICexc | 1.63% | ||
| ROICexgc | 4.36% | ||
| OM | 2.41% | ||
| PM (TTM) | N/A | ||
| GM | 50.47% | ||
| FCFM | 6.15% |
ROA(3y)-14.8%
ROA(5y)-8.25%
ROE(3y)-20.56%
ROE(5y)-11.47%
ROIC(3y)1.82%
ROIC(5y)2.02%
ROICexc(3y)2.02%
ROICexc(5y)2.23%
ROICexgc(3y)5.81%
ROICexgc(5y)7.12%
ROCE(3y)2.3%
ROCE(5y)2.56%
ROICexgc growth 3Y-33.59%
ROICexgc growth 5YN/A
ROICexc growth 3Y-26.31%
ROICexc growth 5YN/A
OM growth 3Y-36.17%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-0.68%
F-Score6
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 2.33 | ||
| Debt/EBITDA | 1.62 | ||
| Cap/Depr | 81.23% | ||
| Cap/Sales | 4.51% | ||
| Interest Coverage | 2.6 | ||
| Cash Conversion | 133.87% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.15 | ||
| Quick Ratio | 1.26 | ||
| Altman-Z | 1.21 |
F-Score6
WACC10.39%
ROIC/WACC0.14
Cap/Depr(3y)52.99%
Cap/Depr(5y)50.85%
Cap/Sales(3y)3.25%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.4%
EPS 3Y-17.1%
EPS 5Y3.8%
EPS Q2Q%-30.95%
EPS Next Y8.62%
EPS Next 2Y16.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.95%
Revenue growth 3Y-5.08%
Revenue growth 5Y-0.38%
Sales Q2Q%0.72%
Revenue Next Year2.16%
Revenue Next 2Y3.19%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-62.19%
EBIT growth 3Y-39.42%
EBIT growth 5YN/A
EBIT Next Year165.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.01%
FCF growth 3Y-15.57%
FCF growth 5YN/A
OCF growth 1Y-25.82%
OCF growth 3Y-6.33%
OCF growth 5YN/A
AVANOS MEDICAL INC / AVNS Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for AVANOS MEDICAL INC?
ChartMill assigns a fundamental rating of 4 / 10 to AVNS.
What is the valuation status for AVNS stock?
ChartMill assigns a valuation rating of 6 / 10 to AVANOS MEDICAL INC (AVNS). This can be considered as Fairly Valued.
Can you provide the profitability details for AVANOS MEDICAL INC?
AVANOS MEDICAL INC (AVNS) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for AVNS stock?
The Earnings per Share (EPS) of AVANOS MEDICAL INC (AVNS) is expected to grow by 8.62% in the next year.